Drugs · acquisition-cost intelligence
MAXIDEX
dexamethasone· ingredient dexamethasoneCorticosteroids· DEXAMETHASONE 1 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$13.21
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other dexamethasone products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Dexamethasone | $0.10682 | −$13.10 |
| Dexamethasone | $0.15403 | −$13.06 |
| Dexamethasone | $0.19895 | −$13.01 |
| TaperDex 12-day | $0.19895 | −$13.01 |
| dexamethasone | $0.20711 | −$13.00 |
| dexamethasone | $0.25646 | −$12.95 |
| Dexamethasone Sodium Phosphate | $0.69334 | −$12.52 |
| Dexamethasone Sodium Phosphate | $0.69334 | −$12.52 |
Medicare Part D coverage · CY2026
On 6 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.